{
    "ASSERTIONS": {
        "id": 700,
        "context": "Metastatic",
        "description": "Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.",
        "disease": {
            "name": "Ovarian Cancer, Other",
            "oncotree_code": "OOVC",
            "oncotree_term": "Ovarian Cancer, Other"
        },
        "therapy_name": "Durvalumab",
        "therapy_type": "Immunotherapy",
        "clinical_significance": "sensitivity",
        "predictive_implication": "Preclinical",
        "favorable_prognosis": null,
        "created_on": "11/04/21",
        "last_updated": "2019-02-04",
        "submitted_by": "breardon@broadinstitute.org",
        "validated": true,
        "source_ids": 51,
        "variant": {
            "id": 700,
            "cytoband": null,
            "direction": "Deletion",
            "feature_type": "copy_number",
            "gene": "ARID1A",
            "feature": "ARID1A Deletion"
        }
    },
    "SOURCES": {
        "id": 51,
        "type": "Journal",
        "doi": "10.1038/s41591-018-0012-z",
        "nct": "None",
        "pmid": 29736026,
        "url": "https://doi.org/10.1038/s41591-018-0012-z",
        "citation": "Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562."
    },
    "VARIANTS": {
        "id": 700,
        "cytoband": null,
        "direction": "Deletion",
        "feature_type": "copy_number",
        "gene": "ARID1A",
        "feature": "ARID1A Deletion"
    }
}